Monday, 2 November 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· July 27, 2026

OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results

View original at finance.yahoo.com

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • OPKO Biologics plans to advance OPK8801001 to clinical trials at the end of 2026.

    60% confidence

  • ModeX plans to enter Phase 1 studies of its in vivo CAR T platform later this year or in early 2027.

    60% confidence

  • OPKO plans to complete enrollment of the MDX2301 trial in Q3 2026, with early data presented in late 2026 or early 2027.

    60% confidence

  • OPK8801001 showed approximately 20-fold greater growth hormone receptor antagonism than established Pegvisomant therapy in vitro.

    60% confidence

  • OPKO expects to report initial safety, tolerability, pharmacokinetic and immune data for MDX2004 in the first half of 2027.

    60% confidence

  • OPKO congratulates Entera Bio on its oversubscribed $275 million private placement, which underscores the strength of its scientific platform.

    60% confidence

  • The MDX2301 trial is being funded by BARDA.

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic AI Goes Operational: Platform Governance, Local Silicon, and the Physical-AI Data Race
In mid-to-late October 2026, enterprise vendors (Cisco, Fortinet, ServiceNow, Intuit, Salesforce/Braze, Adobe) shipped agent governance, AI security and AI-driven customer engagement products, while a parallel hardware wave (NVIDIA RTX Spark laptops, ASUS, Apple's iPad mini, Microsoft's hybrid local/cloud Windows) pushed AI onto local devices. A third strand, physical AI (Encord, Harvest Praxis, Hesai), argues that real-world sensor data and cheaper edge chips are the next bottleneck. The common thread is the shift from AI experimentation to governed, scaled deployment, with Salesforce's Braze acquisition showing consolidation and fintech players like Intuit tying AI to trusted financial data. The facts support a broad industry theme but contain little direct finance or regulatory evidence, so the AI-finance angle is thin.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,533 source documents archived
Query this data → isubstrate.com
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results — Source | Via News | ViaNews EU